81 results
To investigate the genetic, genomic and proteomic basis of hypertension and susceptibility to hypertension-related target-organ damage (renal insufficiency and heart failure).
To determine the general usefulness of and a proper moment when blood should be taken for the in vitro IFN-γ assays in patients undergoing chronic haemodialysis.
The primary objective is to investigate if there is an incremental inhibiting effect on MSNA by increasing dosage valsartan above the presently advised dosage. We hypothesize that there will be a further decrease in MSNA as compared to the MSNA…
The primary objective is to investigate if there is an incremental inhibiting effect on MSNA by increasing dosage valsartan above the presently advised dosage. We hypothesize that there will be a further decrease in MSNA as compared to the MSNA…
The major aim of this project is to elucidate the molecular basis of IgAN. A large cohort of IgAN patients will be screened on aberrancies in the DNA sequence or expression of the gene encoding Cosmc, a protein that is essential for the biosynthesis…
Primary: To prove that infliximab in combination with azathioprine is superior to azathioprine alone in rapidly inducing a meaningful renal improvement, defined as a reduction in preoteinuria of at least 50%, in patients with membranous SLE…
Study whether chloroquine as comedication results in a better respons on Hepatitis B vaccination in non-responder dialysis patients.
Aim of the present study is to compare the effects of low-flux hemodialysis, post-dilution on-line hemodiafiltration, and superflux dialysis with regard to clearance and pre-dialytic levels of larger uremic substances. Moreover, the effects of these…
Main study:Primary objective: What are the long-term effects (i.e. after 8-week drug exposure) of the GLP-1RA versus a single dose prandial insulin onrenal hemodynamics (glomerular filtration rate/ effective renal plasma flow in basal insulin-…
Objective of this study is to compare 1-year garft survival after hypothemic machine perfusion with oxygentaed perfusion solution versus static cold storage of extended criteria kidneys from DBD donors.
The study has 3 objectives: 1. Proving that this form of RCA does not increase the risk of bleeding while achieving a degree of anticoagulation of the extracorporeal system that is similar to that when using LMWH. When this study shows that citrate…
Primary objective: What are the long-term effects (i.e. after 8-week drug exposure) of the DPP-4i linagliptin versus the SU derivative glimepiride on fasting and postprandial renal hemodynamics (glomerular filtration rate (GFR)/ effective renal…
To measure changes in urinary RAS components during an acid-loading test in patients with CKD and healthy controls.
The objective of this study is to investigate the role of inflammatory mediators (circulating platelet activity levels, MP numbers, and levels of plasma/urinary mtDNA) to the occurrence and severity of acute rejection and renal outcome.
The main objective is to study the effect of renal transplantation with a living donor on selected cardiovascular, nutritional and activity parameters in both recipients as well as living donors.
To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics
To compare the effect of a sevoflurane based anesthesia versus a propofol based anesthesia on acute rejection and outcome in recipients of living, DCD and DBD donor kidneys.
1) To study the effects of antibody removal by immunoadsorption on the immune phenotype over time in patients with B-cell related autoimmune diseases such as MG, AAV, anti-GBM disease, cryoglobulinemic vasculitis and other refractory antibody-…
This study has been transitioned to CTIS with ID 2024-516509-22-00 check the CTIS register for the current data. 1. To test the hypothesis that an age adapted immunosuppressive regimen targeted at reduced immunosuppression with low calcineurin…
The purpose of this study is to ascertain the efficacy, safety, tolerability and pharmacokineticsof LNP023 over a 24-week treatment period compared with rituximab in subjects with MN.